This content is generated by AI. You can give feedback on it in the Inderes forum.
ExpreS2ion announced after market close on 19 November that its Board of Directors has resolved to implement a restructuring, including a reduction in workforce, to lower operating costs and prioritise the development and partnering of ES2B-C001, its lead HER2-targeted active immunotherapy. The number of employees will be reduced from 21 to five during 2027.
Financial impact. Compared with the previous plan, operating costs are expected to be reduced by approximately SEK 23m in 2027, as the measures take effect during the year, and by approximately SEK 30m annually from 2028, once the restructuring is fully implemented in the second half of 2027. The Company states operating costs of SEK 56.5m for the full year 2025 and SEK 57.4m for the first nine months of 2026. Restructuring costs, mainly pay during notice periods and severance, are estimated at up to approximately SEK 5m and are expected to be charged largely to Q4 2026. Cash and cash equivalents amounted to SEK 35.8m on 31 October 2026, before settlement of existing liabilities.
Financing. The Company states that the restructuring does not by itself finance operations beyond the Phase I primary read-out, and that the Board is evaluating financing alternatives to fund ongoing working capital needs and the partnering process that follows the read-out. The Company adds that there is no guarantee that such financing can be obtained on acceptable terms, and that the measures do not remove the need for additional financing and partnering to initiate Phase II.
ES2B-C001 and milestones. All 19 patients have been enrolled and started treatment in the Phase I trial in advanced HER2-positive or HER2-low breast cancer. At the 5 October 2026 data cut-off, anti-HER2 antibody responses had been observed in 12 of 13 evaluable patients, with no dose-limiting toxicities and no serious adverse events assessed as related to ES2B-C001, observations the Company describes as preliminary and not establishing clinical benefit. Results from three translational studies of patient sera are expected in December 2026, the last patient’s last visit in the five-dose priming phase is expected at the end of December 2026, and the primary read-out is to be announced in Q1 2027. Phase II initiation remains targeted for the second half of 2027, subject to financing and partnering, Phase I data, regulatory interactions and final protocol development, with planning focused on evaluating ES2B-C001 alongside standard of care in a first-line setting.
Partnered programmes and platform. The malaria programmes continue as partner-led activities, with RH5.1 and R78C covered by the licensing agreement with Serum Institute of India from November 2025. On influenza, the INDIGO consortium concluded in Q1 2026 and no further work is planned without new external funding, while participation in the MucoVax collaboration will be discussed directly with the partners, including any required handover and outstanding grant obligations. The EU-funded VICI-Disease consortium continues towards clinical initiation of a Nipah vaccine during 2027. ExpreS2ion is pursuing strategic partnerships for the ExpreS2 platform and related contract services, will no longer prioritise expansion of its standalone CRO business, and states that the outcome and timing of these discussions remain uncertain.
Management and Board. The management team is unchanged, with CEO Bent U. Frandsen, CSO Max Søgaard and CFO Keith Alexander leading the smaller organisation. Board member Karin Garre steps down at the end of the year as part of reducing her professional commitments, leaving a Board of Martin R. Jensen, Michel Baijot and Jakob Knudsen.
Our take. The restructuring concentrates internal resources on ES2B-C001 while the partnered malaria and Nipah programmes continue under their existing partners and consortia. On our calculation, the approximately SEK 30m annual saving is a little over half the 2025 operating cost base, which is a substantial reduction for a company of this size, and it is achieved without touching the clinical timetable: the December translational results and the Q1 2027 primary read-out both stand, and the leadership that has to carry them remains in place. The trade-off is that platform and contract services value now depends on finding a partner rather than on building the business internally, and the Company is explicit that the timing and outcome of those discussions remain uncertain. The open question is financing. A lower run rate lengthens the Company’s reach, but the Board states that the measures do not on their own fund operations beyond the primary read-out, and the financing alternatives are being evaluated now rather than after the data. In our view, the sequence of the next two events, the Phase I read-out and the terms on which the Company funds itself through the partnering process that follows, is what matters most from here.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotech Holding AB for a Digital IR/Corporate Visibility subscription agreement. Michael Friis, 06:35, 20/11-2026